How can open-label trials be used to study the impact of environmental factors on health outcomes?

This is a first-in-human, Ph 1/2, open-label, multicenter dose escalation and expansion study in advanced solid tumors. The purpose of this preliminary study is to examine the active music therapy on cognition and neuropsychiatric symptoms in the elderly with mild and moderate ... Sep 17, 2024 ... ... Open-Label Trial in Patients with Newly Diagnosed Oligometastatic Prostate Cancer Starting ADT ... The STAMPEDE2 trial is a phase III, randomized, ... Nasal povidone-iodine may be considered as an alternative to mupirocin in a multifaceted approach to reduce SSI. Mar 4, 2025 ... Inclusion Criteria: ... Unresponsive to ≥2 courses of Bacillus Calmette-Guerin (BCG) therapy within the last 12 months. BCG-unresponsive refers to ... This prospective, open-label clinical trial aimed to evaluate the tolerability and the efficacy of B cell depletion for remission induction in IgG4-RD. Carefully designed open-label clinical trials may deliver valuable, high-quality clinical data that can advance the drug development process. This is a phase 2/3 open-label trial to evaluate the long-term safety, tolerability, and efficacy of sibeprenlimab administered subcutaneously (SC) in subjects ... Sep 17, 2024 ... Sarah Howlett discussing the trial design of STAMPEDE2, a phase 3, randomized, open-label trial of niraparib-abiraterone acetate + prednisolone ... Oct 2, 2010 ... Methods. We undertook an open-label randomised phase 3 trial in men with metastatic castration-resistant prostate cancer who had received ...